EP(1) receptor antagonism mitigates early and late stage renal fibrosis

AIM: Renal fibrosis is a major driver of chronic kidney disease, yet current treatment strategies are ineffective in attenuating fibrogenesis. The cyclooxygenase/prostaglandin system plays a key role in renal injury and holds great promise as a therapeutic target. Here, we used a translational appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kresse, Jean‐Claude, Mutsaers, Henricus A. M., Jensen, Michael Schou, Tingskov, Stine Julie, Madsen, Mia Gebauer, Nejsum, Lene N., Prætorius, Helle, Nørregaard, Rikke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Renal Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286353/
https://www.ncbi.nlm.nih.gov/pubmed/34989478
http://dx.doi.org/10.1111/apha.13780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286353/
https://www.ncbi.nlm.nih.gov/pubmed/34989478
http://dx.doi.org/10.1111/apha.13780

Ejemplares similares